Takeaway: New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial

Last updated: 02/07/2026 22:07

0 Min Read

A phase 2 trial published in NEJM shows promise for daraxonrasib, a novel targeted therapy for previously treated metastatic pancreatic cancer. The study compared the new drug to standard chemotherapy in this challenging patient population. — Photo: Tara Winstead / Pexels

1 min read|39 words

Key takeaways from new pancreatic cancer study: 1) Novel targeted therapy tested in phase 2 trial 2) Compared to standard chemotherapy in previously treated patients 3) Results published in NEJM provide evidence for potential new treatment option

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Takeaway

📰 Read the full article: New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial →

Share This Article

ByProf. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Takeaway: New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial

Submit Your Paper →

England’s Euro 2024 Match Days Saw 17,000 Fewer A&E Visits — Why That Matters for Health Planning

Americas Health Leadership: PAHO Executive Committee Endorses Plan to Strengthen Regional Health Systems

UK Orphan Drug Registry Expands Access to Rare Disease Treatments

Submit Your Paper to GMJ

Company

You Might Also Like